Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma
2019-02-28 08:30
Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards
2019-02-27 12:00
Blackford Analysis Commended by Frost & Sullivan for its Visionary Implementation of Platform-based Approaches in the Medical Imaging Space
2019-02-26 22:00
Cachet Asset Management to Lead the Latest Round of Funding for ProTom International Holding Company
2019-02-26 19:22
Focusing on Advanced Laboratory Instruments and Equipment, Building an All-around Live-action Space -- 2019 InnoLAB Salon Formally Kicked Off
2019-02-26 15:00
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
2019-02-26 08:23
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
2019-02-26 08:07
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
2019-02-26 08:07
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2019
2019-02-26 05:16
Top 3 Growth Opportunities for Digital Pathology-enabling Technology Companies
2019-02-26 03:13
Mallinckrodt Announces Extracorporeal Photopheresis (ECP) Research Collaboration Agreement With Transimmune AG
2019-02-25 22:00
Texas Cardiac Arrhythmia Institute at St. David's Medical Center enrolling patients to test stroke-reducing device
2019-02-25 10:08
Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection) as Part of the National Mega Innovation Program in Beijing
2019-02-22 15:02
PharmaEssentia and AOP Orphan Receive EU Approval of Besremi™ (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU
2019-02-22 06:13
Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
2019-02-21 16:00
Cipla and Wellthy Therapeutics Announce Partnership to Offer Digital Therapeutics for Diabetes and Cardiovascular Diseases
2019-02-21 07:30
Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey
2019-02-20 19:07
Future of Clinical Laboratories: How to Adapt Your Strategy to the Declining Reimbursements and Be Successful
2019-02-19 21:20
Merck Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
2019-02-19 21:00
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2019 Financial Results
2019-02-19 19:00
1
430
431
432
433
434
531